Clinical factors associated with leptomeningeal disease in patients with melanoma brain metastasis

Clicks: 13
ID: 328891
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #124 of 144 articles by views in Neuro-Oncology Advances

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 144 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Leptomeningeal disease (LMD) is a severe manifestation of metastatic cancer with limited treatment options and a poor prognosis. Melanoma has one of the highest rates of leptomeningeal spread among solid tumors. Given the associated morbidity and mortality, identifying clinical factors linked to LMD in patients with melanoma brain metastases (MBM) is crucial. Methods We conducted a retrospective study of 829 MBM patients diagnosed at MD Anderson Cancer Center (2009-2018). The primary outcome measure was time from MBM-to-LMD. Cumulative incidence of LMD was determined using the competing risks method, where death was the competing risk. Differences in cumulative incidences were assessed using Gray’s test, and associations between measures of interest and cumulative incidence were determined using proportional sub-distribution hazards models. Results Among 829 patients, 129 (16%) developed LMD (median follow-up: 12.1 months, range: 0.03-156 months). Median time from MBM diagnosis to LMD was 5.5 months. Of those with known mutation status (n = 713), BRAF V600 mutation was present in 74% of patients who developed LMD versus 50% in those who did not (p < 0.001). Multivariable analysis (MVA) showed BRAF V600 mutation (p = 0.009) and craniotomy (p = 0.035) were associated with the development of LMD. In a sub-analysis of BRAF V600 mutant patients (n = 380), MVA revealed that primary melanoma site (upper extremity vs. head/neck) and number of MBMs at diagnosis were associated with LMD development. Conclusion LMD is a dire consequence of advanced melanoma, yet the clinical features associated with its development are not fully characterized. Identifying clinical predictors may guide management of high-risk populations.
Reference Key
openalex_W7213297369 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Merve Hasanov, Christina Abi Faraj, Denái R. Milton, Subasree Srinivasan, Eric A. Goethe, Ian E McCutcheon, Jeffrey S Weinberg, Isabella C Glitza Oliva, Sherise D Ferguson
Are you one of these authors? Claim your profile
Journal Neuro-Oncology Advances
Year 2026
DOI
10.1093/noajnl/vdag232
URL
https://academic.oup.com/noa/advance-article-pdf/doi/10.1093/noajnl/vdag232/71089458/vdag232.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.